Zinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low‐dose D‐penicillamine
- 1 June 1991
- journal article
- case report
- Published by Wiley in Journal of Internal Medicine
- Vol. 229 (6) , 549-552
- https://doi.org/10.1111/j.1365-2796.1991.tb00395.x
Abstract
A 30-year-old woman with Wilson's disease was treated with low-dose D-penicillamine. After 12 days, treatment was changed to zinc sulphate because of severe neurological deterioration. The patient subsequently improved within a few days. During a follow-up period of 20 months, the effectiveness of therapy was evaluated by measuring copper and zinc levels in plasma and urine, and by 64Cu-loading tests. We conclude that sulphate therapy may be a satisfactory alternative, even when rapid deterioration occurs in the early stages of D-penicillamine treatment.Keywords
This publication has 9 references indexed in Scilit:
- Morbus Wilson - kritische Verschlechterung unter hochdosierter parenteraler Penicillamin-TherapieDeutsche Medizinische Wochenschrift (1946), 1990
- The Use of Trientine in Preventing the Effects of Interrupting Penicillamine Therapy in Wilson's DiseaseNew England Journal of Medicine, 1987
- Worsening of Neurologic Syndrome in Patients With Wilson's Disease With Initial Penicillamine TherapyArchives of Neurology, 1987
- Management of Wilson's disease with zinc sulphateJournal of the Neurological Sciences, 1987
- Effective treatment of Wilson's disease with oral zinc sulphate: two case reports.BMJ, 1984
- Treatment of Wilson's DiseaseAnnals of Internal Medicine, 1983
- Oral Zinc Therapy for Wilson's DiseaseAnnals of Internal Medicine, 1983
- Caeruloplasmin: A Multi‐Functional Metalloprotein of Vertebrate PlasmaPublished by Wiley ,1980
- Prevention of Wilson's Disease in Asymptomatic PatientsNew England Journal of Medicine, 1968